You are here

Ocrelizumab for primary progressive MS

Over 21,000 people have called for a treatment for primary progressive MS to be made available.

In September, the National Institute for Health and Care Excellence (NICE) rejected ocrelizumab being made available for early primary progressive MS. This was because they think it costs too much for the benefi ts it can provide.

As a result, we launched a petition calling for the manufacturer Roche, NICE and NHS England to put patients first and agree a deal to make ocrelizumab available at a price the NHS can afford.

It didn’t take long for thousands of people to join the call and within a few weeks the petition had over 21,000 signatures. Thank you to all of you who signed the petition.

This isn’t the end. The significance of this treatment cannot be understated.

We’ll be doing everything we can to ensure the drug is available to everyone who could benefit. We want to reverse the decision, or find alternative routes to access.

To get involved and find out more please join our Campaigns Community and add your voice. Visit mssociety.org.uk/campaigns

  1. Back to Teamspirit 221